Agnes E Hamburger
Overview
Explore the profile of Agnes E Hamburger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Partin A, Bruno R, Shafaattalab S, Mause E, Winters A, Daris M, et al.
Front Immunol
. 2024 Feb;
15:1304765.
PMID: 38343543
Clinical applications of CAR-T cells are limited by the scarcity of tumor-specific targets and are often afflicted with the same on-target/off-tumor toxicities that plague other cancer treatments. A new promising...
2.
Tokatlian T, Asuelime G, Naradikian M, Mock J, Daris M, Martin A, et al.
Cancer Res Commun
. 2023 Mar;
2(1):58-65.
PMID: 36860694
Significance: We report an effort to generate high potency, selective CARs directed at mutant KRAS peptides. Although the heavily optimized CARs maintain high selectivity against wild-type KRAS, they lose selectivity...
3.
Mock J, Winters A, Riley T, Bruno R, Naradikian M, Sharma S, et al.
Mol Ther Oncolytics
. 2022 Nov;
27:157-166.
PMID: 36381658
Innovative cell-based therapies are important new weapons in the fight against difficult-to-treat cancers. One promising strategy involves cell therapies equipped with multiple receptors to integrate signals from more than one...
4.
DiAndreth B, Hamburger A, Xu H, Kamb A
Clin Immunol
. 2022 May;
241:109030.
PMID: 35561999
Immune cells that are engineered with receptors to integrate signals from multiple antigens offer a promising route to achieve the elusive property of therapeutic selectivity in cancer patients. Several types...
5.
Tokatlian T, Asuelime G, Mock J, DiAndreth B, Sharma S, Toledo Warshaviak D, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35091455
Background: Mesothelin (MSLN) is a classic tumor-associated antigen that is expressed in lung cancer and many other solid tumors. However, MSLN is also expressed in normal mesothelium which creates a...
6.
Hamburger A, DiAndreth B, Cui J, Daris M, Munguia M, Deshmukh K, et al.
Mol Immunol
. 2020 Oct;
128:298-310.
PMID: 33012527
We describe an approach to cancer therapy based on exploitation of common losses of genetic material in tumor cells (loss of heterozygosity) (Basilion et al., 1999; Beroukhim et al., 2010)....
7.
Xu H, Hamburger A, Mock J, Wang X, Martin A, Tokatlian T, et al.
Mol Immunol
. 2020 Aug;
126:56-64.
PMID: 32768859
Chimeric antigen receptors (CARs) and their parent signaling molecule, the T cell receptor (TCR), are fascinating proteins of increasing relevance to disease therapy. Here we use a collection of 1221...
8.
Arora T, Padaki R, Liu L, Hamburger A, Ellison A, Stevens S, et al.
Cytokine
. 2009 Jan;
45(2):124-31.
PMID: 19128982
There are currently two Food and Drug Administration-approved classes of biologic agents that target tumor necrosis factor-alpha (TNF-alpha): anti-TNF monoclonal antibodies (mAbs) (adalimumab and infliximab), and soluble TNF receptors (etanercept)....
9.
Hamburger Z, Hamburger A, West Jr A, Weis W
J Mol Biol
. 2005 Dec;
356(1):9-21.
PMID: 16359701
The exocyst is an evolutionarily conserved multiprotein complex required for the targeting and docking of post-Golgi vesicles to the plasma membrane. Through its interactions with a variety of proteins, including...
10.
Hamburger A, West Jr A, Hamburger Z, Hamburger P, Bjorkman P
J Mol Biol
. 2005 May;
349(3):558-69.
PMID: 15896348
Ferritins are iron storage proteins made of 24 subunits forming a hollow spherical shell. Vertebrate ferritins contain varying ratios of heavy (H) and light (L) chains; however, known ferritin structures...